RubenReyesMD
Hematology • Westwood, KSAssistant Professor, Internal Medicine, University Kansas School of Medicine
Dr. Reyes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2330 Shawnee Mission Pkwy
Suite 210
Westwood, KS 66205Phone+1 913-588-6029Fax+1 252-744-3418- Is this information wrong?
Education & Training
Vidant Medical Center/East Carolina UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
MetroWest Medical CenterResidency, Internal Medicine, 2002 - 2005
Superior Institute of Medical Sciences of Santiago de CubaClass of 1986
Certifications & Licensure
KS State Medical License 2009 - 2015
Clinical Trials
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine Start of enrollment: 2010 Jan 01
- A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer Start of enrollment: 2011 Feb 01
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Publications & Presentations
PubMed
- 281 citationsComplete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell LymphomaMark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Steven M. Horwitz, Dennis D. Weisenburger, Jun Liu, Elizabeth A. Morgan, Ra...> ;Journal of Clinical Oncology. 2016 Sep 19
- 14 citationsLocally Advanced Breast Implant-Associated Anaplastic Large-Cell Lymphoma: A Case Report of Successful Treatment with Radiation and ChemotherapyChristopher Fleighton Estes, Da Zhang, Ruben Reyes, Richard Korentager, Marilee McGinness, C.E. Lominska> ;Frontiers in Oncology. 2015 Feb 18
- 42 citationsPhase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Sarit Assouline, Julie E. Chang, Bruce D. Cheson, Robert M. Rifkin, Solomon I. Hamburg, Ruben Reyes, A-M Hui, Jiang Yu, Neeraj Gupta, A Di Bacco, Yaping Shou, Peter Ma...> ;Blood Cancer Journal. 2014 Oct 17
- Join now to see all
Hospital Affiliations
The University of Kansas HospitalKansas City, Kansas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
